A novel selective small-molecule PI3K inhibitor is effective against human multiple myeloma in vitro and in vivo

Blood Cancer Journal

Volumn 3, Issue 9, 2013, Pages

  Glauer, J ^a   Pletz, N ^a   Schon M ^a   Schneider, P ^a   Liu, N ^b   Ziegelbauer, K ^b   Emmert, S ^a   Wulf, G G ^a   Schon M P ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

Chemoresistance; Myeloma; PI3 kinase

Indexed keywords

COPANLISIB; GLYCOGEN SYNTHASE KINASE 3; PROTEIN KINASE B; SOMATOMEDIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE PHASE; CELL CYCLE PROGRESSION; CELL VIABILITY; CONTROLLED STUDY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PROTEIN PHOSPHORYLATION;

EID: 84885350783     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2013.37     Document Type: Article

References (49)

1. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet 2009; 374: 324-339.
2. Attal M, Harousseau J-L, Facon T, Guilhot F, Doyen C, Fuzibet JG et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-2505.
3. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351: 1860-1873.
4. Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a populationbased study. Nordic Myeloma Study Group. Blood 2000; 95: 7-11. (Pubitemid 30017218)
5. Richardson P, Hideshima T, Anderson KC. An update of novel therapeutic approaches for multiple myeloma. Curr Treat Options Oncol 2004; 5: 227-238. (Pubitemid 39359623)
6. Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002; 2: 927-937. (Pubitemid 37328894)
7. Schwarzenbach H. Expression of MDR1/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma. Med Oncol 2002; 19: 87-104. (Pubitemid 34625930)
8. Hazlehurst LA, Damiano JS, Buyuksal I, Pledger WJ, Dalton WS. Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 2000; 19: 4319-4327.
9. Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 2001; 20: 4519-4527. (Pubitemid 32772434)
10. Landowski TH, Olashaw NE, Agrawal D, Dalton WS. Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB/p50) in myeloma cells. Oncogene 2003; 22: 2417-2421. (Pubitemid 36560725)
11. Mitsiades CS, Mitsiades N, Munshi NC, Anderson KC. Focus on multiple myeloma. Cancer Cell 2004; 6: 439-444. (Pubitemid 39469979)
12. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004; 5: 221-230. (Pubitemid 38402114)
13. Sprynski AC, Hose D, Caillot L, Reme T, Shaughnessy JDJ, Barlogie B et al. The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood 2009; 113: 4614-4626.
14. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 2012; 12: 159-169.
15. Toker A, Cantley LC. Signalling through the lipid products of phosphoinositide- 3-OH kinase. Nature 1997; 387: 673-676. (Pubitemid 27270600)
16. Martelli AM, Evangelisti C, Chappell W, Abrams SL, Bäsecke J, Stivala F et al. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia 2011; 25: 1064-1079.
17. Downward J. PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol 2004; 15: 177-182.
18. Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 2005; 55: 178-194. (Pubitemid 40826487)
19. Bartholomeusz C, Gonzalez-Angulo AM. Targeting the PI3K signaling pathway in cancer therapy. Expert Opin Ther Targets 2012; 16: 121-130.
20. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275: 1943-1947. (Pubitemid 27148818)
21. Maehama T. PTEN: its deregulation and tumorigenesis. Biol Pharm Bull 2007; 30: 1624-1627. (Pubitemid 47403234)
22. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006; 441: 424-430. (Pubitemid 44050136)
23. Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She QB, Maurer M et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA 2007; 104: 7564-7569. (Pubitemid 47185946)
24. Neri A, Marmiroli S, Tassone P, Lombardi L, Nobili L, Verdelli D et al. The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines. Leuk Lymphoma 2008; 49: 1374-1383. (Pubitemid 352015802)
25. Pene F, Claessens YE, Muller O, Viguie F, Mayeux P, Dreyfus F et al. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene 2002; 21: 6587-6597. (Pubitemid 35177037)
26. Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006; 107: 4053-4062. (Pubitemid 43726814)
27. Shimizu S, Takiguchi T, Fukutoku M, Yoshioka R, Hirose Y, Fukuhara S et al. Establishment of a CD4-positive plasmacytoma cell line (AMO-1). Leukemia 1993; 7: 274-280. (Pubitemid 23079240)
28. Ohtsuki T, Yawata Y, Wada H, Sugihara T, Mori M, Namba M. Two human myeloma cell lines, amylase-producing KMS-12-PE and amylase-non-producing KMS-12-BM, were established from a patient, having the same chromosome marker, t(11;14)(q13;q32). Br J Haematol 1989; 73: 199-204. (Pubitemid 19256112)
29. Matsuo Y, Drexler HG, Harashima A, Okochi A, Hasegawa A, Kojima K et al. Induction of CD28 on the new myeloma cell line MOLP-8 with t(11;14) (q13;q32) expressing delta/lambda type immunoglobulin. Leuk Res 2004; 28: 869-877. (Pubitemid 38760049)
30. Schwab G, Siegall CB, Aarden LA, Neckers LM, Nordan RP. Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U-266. Blood 1991; 77: 587-593.
31. Alkan S, Izban KF. Immunohistochemical localization of phosphorylated AKT in multiple myeloma. Blood 2002; 99: 2278-2279. (Pubitemid 34525528)
32. Hsu J, Shi Y, Krajewski S, Renner S, Fisher M, Reed JC et al. The AKT kinase is activated in multiple myeloma tumor cells. Blood 2001; 98: 2853-2855.
33. Tu Y, Gardner A, Lichtenstein A. The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. J Biomol Screen 2002; 7: 441-450.
34. Fuchikami K, Togame H, Sagara A, Satho T et al. A versatile high-throughput screen for inhibitors of lipid kinase activity: development of an immobilized phospholipid plate assay for phosphoinositide 3-kinase gamma. Cancer Res 2000; 60: 6763-6770.
35. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91: 231-241. (Pubitemid 27456390)
36. Hemmings BA. Akt signaling: linking membrane events to life and death decisions. Science 1997; 275: 628-630. (Pubitemid 27061321)
37. Hideshima T, Chauhan D, Richardson P, Anderson KC. Identification and validation of novel therapeutic targets for multiple myeloma. J Clin Oncol 2005; 23: 6345-6350. (Pubitemid 46218845)
38. Franke TF, Hornik CP, Segev L, Shostak GA, Sugimoto C. PI3K/Akt and apoptosis: size matters. Oncogene 2003; 22: 8983-8998. (Pubitemid 38121699)
39. Podar K, Tai YT, Davies FE, Lentzsch S, Sattler M, Hideshima T et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 2001; 98: 428-435.
40. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3- kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008; 7: 1851-1863.
41. Ghobrial IM, Leleu X, Hatjiharissi E, Hideshima T, Mitsiades C, Schlossman R et al. Emerging drugs in multiple myeloma. Expert Opin Emerg Drugs 2007; 12: 155-163. (Pubitemid 46490736)
42. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617. (Pubitemid 36741588)
43. Hideshima T, Nakamura N, Chauhan D, Anderson KC. Biologic sequelae of interleukin- 6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 2001; 20: 5991-6000. (Pubitemid 32955041)
44. Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D et al. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 2002; 21: 5673-5683. (Pubitemid 35333000)
45. van de Donk NWCJ, Lokhorst HM, Bloem AC. Growth factors and antiapoptotic signaling pathways in multiple myeloma. Leukemia 2005; 19: 2177-2185. (Pubitemid 41741612)
46. Podar K, Raab MS, Zhang J, McMillin D, Breitkreutz I, Tai YT et al. Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Blood 2007; 109: 1669-1677. (Pubitemid 46239601)
47. Urashima M, Chen BP, Chen S, Pinkus GS, Bronson RT, Dedera DA et al. The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood 1997; 90: 754-765. (Pubitemid 27299116)
48. Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol 2010; 21: 325-330.
49. Lentzsch S, Chatterjee M, Gries M, Bommert K, Gollasch H, Dö rken B et al. PI3-K/ AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells. Leukemia 2004; 18: 1883-1890. (Pubitemid 39530020)